title: Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy.
abstract: OBJECTIVE
  A phase II trial was performed to evaluate the efficacy, tolerance, and pharmacokinetic profiles of oral vinorelbine (Navelbine). Oral Navelbine (NVB; Pierre Fabre Médicament, Boulogne, France) was given as first-line chemotherapy for locally advanced or metastatic breast carcinoma (ABC).
  
  
  METHODS
  Sixty-four patients were entered to receive oral NVB on a weekly basis for a total of 8 weeks unless progression or toxicity occurred. Oral NVB was given at 60 mg/m(2) weekly for the first three administrations and was increased to 80 mg/m(2) for the subsequent administrations if there was no grade 4 neutropenia or no more than one episode of grade 3 neutropenia. Patients with objective response or stable disease continued treatment up to a total of 12 weeks or more.
  
  
  RESULTS
  Fifty-eight evaluable patients were included in our study. Four patients (6.9%) had complete responses, and 14 (24.1%) had partial responses, for an overall response rate of 31% (95% CI, 19% to 43%). Median progression-free survival was 17.4 weeks. Median overall survival is not yet reached. There were no treatment-related deaths. The main toxicity was neutropenia: grade 4 in 17.2% of the patients, and 1.8% of administrations and associated clinical serious events in 4 patients (6.2%). Grade 3 and 4 nausea and/or vomiting were noted in 3.1% and 4.6% of the patients, respectively. Only one patient developed grade 3 neuroconstipation. An analysis of Quality of Life Questionnaire C30 forms revealed no significant alteration between baseline and weeks 8 and 16 in global quality of life.
  
  
  CONCLUSIONS
  Oral NVB at this schedule is an effective and well-tolerated agent in the treatment of ABC and offers a promising alternative to the intravenous route. Combination studies are ongoing.
authors.affiliation: Hospices Civils de Lyon, Department of Medical Oncology and EA 643, Université Claude Bernard Lyon I, France.
authors.forename: G
authors.initials: G
authors.lastname: Freyer
authors.forename: T
authors.initials: T
authors.lastname: Delozier
authors.forename: M
authors.initials: M
authors.lastname: Lichinister
authors.forename: D
authors.initials: D
authors.lastname: Gedouin
authors.forename: P
authors.initials: P
authors.lastname: Bougnoux
authors.forename: P
authors.initials: P
authors.lastname: His
authors.forename: K
authors.initials: K
authors.lastname: Imadalou
authors.forename: V
authors.initials: V
authors.lastname: Trillet-Lenoir
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000494:pharmacology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D008875:Middle Aged; D011788:Quality of Life; D012426:Russia / Q000453:epidemiology; D015996:Survival Rate; D014747:Vinblastine / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000494:pharmacology; D000077235:Vinorelbine
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D000077235:Vinorelbine